947182-25-4
Chemical Structure
RO5068760
- CAS No.: 947182-25-4
- Formula:C28H27FIN3O6
- Molecular Weight:647.43
IUPAC Name: (2S,3S)-2-((R)-4-(4-((R)-2,3-dihydroxypropoxy)phenyl)-2,5-dioxoimidazolidin-1-yl)-N-(2-fluoro-4-iodophenyl)-3-phenylbutanamide
InChIKey: MEPDJWRMAAUPBM-VGUPLNMOSA-N
SMILES: C[C@@H](C1=CC=CC=C1)[C@H](N2C([C@@H](C3=CC=C(C=C3)OC[C@H](O)CO)NC2=O)=O)C(NC4=C(C=C(C=C4)I)F)=O
Biological Activity: RO5068760 is a potent, orally active and selective non-ATP-competitive MEK1/2 inhibitor with an IC50 of 0.025 μM for MEK1. RO5068760 significantly inhibits MAPK pathway activity, thereby inducing G1 cell cycle arrest and apoptosis to inhibit cancer cell growth. RO5068760 exhibits significant efficacy in a broad spectrum of tumors with aberrant MAPK pathway activation. RO5068760 can be used for melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer research[1].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RO5068760 | RO5068760 is a potent, orally active and selective non-ATP-competitive MEK1/2 inhibitor with an IC50 of 0.025 μM for MEK1. RO5068760 significantly inhibits MAPK pathway activity, thereby inducing G1 cell cycle arrest and apoptosis to inhibit cancer cell growth. RO5068760 exhibits significant efficacy in a broad spectrum of tumors with aberrant MAPK pathway activation. RO5068760 can be used for melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
